Interestingly in patients with advanced cancer treated with α-GalCer an increase in CMV specific memory CD8+ T cells was observed [54] suggesting that α-GalCer or an α-GalCer analog could also be used therapeutically to control latent infection when the immune system is impaired. The gene discussed is CD8A; the disease is disease arising from reactivation of latent virus.